Literature DB >> 9473003

Ludwig Symposium on biliary disorders--part II. Pathologic features and evolution of primary biliary cirrhosis and primary sclerosing cholangitis.

P J Scheuer1.   

Abstract

Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) share many clinical and pathologic features. Central to the symptoms and biochemical alterations of both conditions is a substantial loss of intrahepatic bile ducts, leading to interference with bile flow. This pathologic change may ultimately result in cirrhosis of the biliary type. In addition, however, biopsy specimens usually show an element of liver-cell destruction and associated inflammation, mainly interface hepatitis. This finding is more pronounced in PBC than in PSC but can lead in both diseases to features that resemble those of cirrhosis as a result of hepatitis virus infection. The resemblance often leads to diagnostic confusion, which is easily overcome by attention to the clinical, radiologic, serologic, and biochemical context. Histologic staging of PBC and PSC has led to a greater appreciation of their evolution but is hampered in biopsy material by sampling error. Examination of explanted livers at transplantation has demonstrated a wide variation in the maturation of lesions in various parts of the organ.

Entities:  

Mesh:

Year:  1998        PMID: 9473003     DOI: 10.4065/73.2.179

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  23 in total

1.  Performance of magnetic resonance elastography in primary sclerosing cholangitis.

Authors:  John E Eaton; Bogdan Dzyubak; Sudhakar K Venkatesh; Thomas C Smyrk; Gregory J Gores; Richard L Ehman; Nicholas F LaRusso; Andrea A Gossard; Konstantinos N Lazaridis
Journal:  J Gastroenterol Hepatol       Date:  2016-06       Impact factor: 4.029

Review 2.  Primary sclerosing cholangitis: updates in diagnosis and therapy.

Authors:  Piero Portincasa; Michele Vacca; Antonio Moschetta; Michele Petruzzelli; Giuseppe Palasciano; Karel J van Erpecum; Gerard P van Berge-Henegouwen
Journal:  World J Gastroenterol       Date:  2005-01-07       Impact factor: 5.742

3.  Histologic features of steatohepatitis in patients with a clinical diagnosis of autoimmune cholestasis.

Authors:  Diego Sánchez-Muñoz; Victor M Castellano-Megías; Manuel Romero-Gómez
Journal:  Dig Dis Sci       Date:  2004 Nov-Dec       Impact factor: 3.199

4.  The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.

Authors:  Gideon M Hirschfield; Jessica K Dyson; Graeme J M Alexander; Michael H Chapman; Jane Collier; Stefan Hübscher; Imran Patanwala; Stephen P Pereira; Collette Thain; Douglas Thorburn; Dina Tiniakos; Martine Walmsley; George Webster; David E J Jones
Journal:  Gut       Date:  2018-03-28       Impact factor: 23.059

5.  A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis.

Authors:  Mittermayer Santiago; Murray Baron; Kiyomitsu Miyachi; Marvin J Fritzler; M Abu-Hakima; S Leclercq; M Bell; M Hudson; J-P Mathieu; S Taillefer; N Jones; P Docherty; M Khraishi; J Markland; J Pope; D Robinson; D Smith; E Sutton
Journal:  Clin Rheumatol       Date:  2007-06-15       Impact factor: 2.980

6.  Embolization of cyanoacrylate glue in systemic circulation in a case of hepatocellular carcinoma: an autopsy report.

Authors:  Kirti Gupta; Rakesh K Vasishta; Usha Dutta; Rakesh K Kochhar; Kartar Singh
Journal:  Diagn Pathol       Date:  2009-12-09       Impact factor: 2.644

Review 7.  Animal models of primary biliary cirrhosis.

Authors:  Ya-Hui Chuang; William M Ridgway; Yoshiyuki Ueno; M Eric Gershwin
Journal:  Clin Liver Dis       Date:  2008-05       Impact factor: 6.126

8.  Autoantibodies from primary biliary cirrhosis patients with anti-p95c antibodies bind to recombinant p97/VCP and inhibit in vitro nuclear envelope assembly.

Authors:  K Miyachi; Y Hirano; T Horigome; T Mimori; H Miyakawa; Y Onozuka; M Shibata; M Hirakata; A Suwa; H Hosaka; S Matsushima; T Komatsu; H Matsushima; R W Hankins; M J Fritzler
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

Review 9.  Primary sclerosing cholangitis.

Authors:  Marina G Silveira; Keith D Lindor
Journal:  Can J Gastroenterol       Date:  2008-08       Impact factor: 3.522

Review 10.  Clinical features and management of primary sclerosing cholangitis.

Authors:  Marina-G Silveira; Keith-D Lindor
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.